Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amlexanox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.98 |
| ▸ | TBK1 | Q9UHD2 | 20/20 | 0.98 |
| ▸ | IKBKE | Q14164 | 12/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | TTR | P02766 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | PKM | P14618 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amlexanox SCHEMBL29381739 | 0.99 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL5058549 | 0.99 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL29642 | 0.99 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL29441547 | 0.99 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL2908304 | 0.98 | TBK1 (0.98) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL2902814 | 0.98 | TBK1 (0.98) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL16216144 | 0.92 | TBK1 (0.87) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19180152 | 0.90 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL16216162 | 0.89 | TBK1 (0.82) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19197522 | 0.89 | TBK1 (0.81) | TBK1IKBKEKDM4ENPC1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968981-B1 | AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS | SUPRATEK PHARMA INC (CA) | 2010-08-18 | — | — | EP | disclosed |
| US-7772255-B2 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| EP-1968981-A4 | A METHOD OF TREATING TUMORS WITH AZAXANTHONES | SUPRATEK PHARMA INC (CA) | 2009-04-15 | — | — | EP | disclosed |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | SEMOV ALEXANDRE | 2009-02-12 | — | — | US | disclosed |
| EP-1968981-A2 | A METHOD OF TREATING TUMORS WITH AZAXANTHONES | Supratek Pharma Inc. (CA) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008020269-A2 | A METHOD OF TREATING TUMORS WITH AZAXANTHONES | SUPRATEK PHARMA, INC. (CA) | 2008-02-21 | — | — | WO | disclosed |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135473-A1 | Method of treating tumors with azaxanthones | S100A4, S100B, S100P | PDE4D 4225/4885TBK1 2135/4885IKBKE 1437/4885 |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | S100A4, S100P, S100B | PDE4D 4295/4885TBK1 2247/4885IKBKE 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.